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A
 
BSTRACT
 
Autoimmune hepatitis (AIH) represents a chronic liver
disease with a progressive nature. Cortocosteroid
therapy is routinely used to control this pathological
condition. Herein, we describe a case of AIH with
spontaneous remission and exacerbation. A previously
healthy young Japanese woman presented with
features of acute hepatitis. The patient was not acutely
infected with hepatotrophic viruses and the possibility
of drug-induced AIH was also excluded. A diagnosis of
AIH was made from subjective symptoms and labora-
tory data, which showed increased levels of liver
enzymes, total bilirubin, IgG and positive titers of anti-
nuclear antibody. Finally, liver biopsy revealed an
expansion of portal tracts and infiltration of mono-
nuclear cells, including plasma cells. This patient
experienced a total of three episodes of acute exacer-
bation of AIH during the past 5 years, two of which
subsided spontaneously. An immunosuppressive drug
was used to control the last episode of acute exacerba-
tion of AIH, which was very similar to acute hepatitis.
The immunosuppressive drug was withdrawn 7 months
after the last epoisode of acute exacerbation of AIH
and the patient is now passing an uneventful course.
There are cases of spontaneous remission and acute
exacerbation of AIH, although the underlying mecha-
nism of this pathological process is yet to be deter-
mined. Liver biopsy is needed to diagnose these cases.
Periodic follow up of these patients is required for
proper management.
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I
 
NTRODUCTION
 
Autoimmune hepatitis (AIH) represents a type of
chronic liver disease with an autoimmune etiology
that is characterized by female predominance, hyper-
gammaglobulinemia and the presence of auto-antibodies
in the sera.
 
1–3
 
 Diagnosis of AIH is based on clinical,
biochemical and histopathological findings. Exclusion of
identifiable viruses, drugs, primary biliary cirrhosis,
Wilson’s disease and hemochromatosis is essential to
diagnose AIH. The presence of plasma cells in the liver
is helpful to make a histological diagnosis. Most patients
with AIH show very good responses to immunosuppres-
sive therapy.
 
4
 
 The disease usually runs a progressive
courses, although an acute pattern of AIH has been
described recently.
 
5,6
 
 In both chronic and acute patterns
of AIH, immunosuppressive drugs are routinely used to
bring about a remission. Spontaneous remission of AIH
is an unusual phenomenon and only a few such cases
have been reported.
 
7
 
 Herein, we report on a patient with
AIH who had three episodes of acute exacerbation and
subsequent remission of AIH; two of these remissions
were achieved without any immunosuppressive drugs.
 
C
 
LINICAL
 
 
 
SUMMARY
 
The patient was a 29-year-old woman. Her family
history was non-contributing to her present illness and
the patient was free from history of allergic diseases
and had never had a blood transfusion. She was not
even a habitual smoker or a social drinker. On
14 September 1998, the patient was referred to Ehime
University Hospital from a nearby hospital for evaluation
of her liver function test.
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The patient’s past history showed that she was admit-
ted into the local hospital on 10 December 1996 with a
complaint of general fatigue, jaundice, fever, itching,
upper abdominal discomfort and arthalgia of the left hip
joint. She was not using any medication prior to her
admission at that time. The clinical course of this patient
is summarized in Fig. 1. Biochemical tests revealed that
she had very high levels of serum bilirubin (5.48 mg/dL),
asparate aminotransferase (AST; 1334 IU/L), alanine
aminotransferase (ALT; 1652 IU/L), γ-glutamyltrans-
peptidase (γ-GTP; 122 IU/L) and alkaline phosphatase
(ALP; 277 IU/L). Although the peripheral blood cell
counts and the levels of hemoglobin were within the
normal range, urinary bilirubin was detected during
urinalysis. The patient was negative for all viral markers
and had a normal thyroid function test. The lupus erythro-
matosus phenomenon was negative and the titer of
antinuclear antibodies (ANA) was 1 : 80 with a homoge-
neous and speckled type of staining. The only abnormal
finding on abdominal ultrasonography was the thickness
of the gall-bladder. Abdominal ultrasongraphy, com-
puted tomography and magnetic resonance cholangio-
graphy revealed that there was no dilatation of the
common bile duct or swelling of the gall-bladder.
The patient was diagnosed as acute hepatitis and was
given intravenous Stronger Neo Minophagen C (SNMC;
Fig. 1 Clinical course of the patient with autoimmune hepatitis (AIH). (a) The drugs used. (b) Levels of total bilirubin (TBil; ) and
IgG (). (c) Levels of alanine aminotransferase (ALT; ),  aspartate aminotransferase (AST; ) and γ
 
-glutamyl transpeptidase
(g-GTP; 
 

 
). Liver biopsy was performed twice, once on 1 October 1998  and then on 23 October 2001. UDCA, ursodeoxycholic
acid; SNMC, Stronger Neo Minophagen C (Minophagen Pharmaceutical, Tokyo, Japan); ANA, antinuclear antibodies.
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Minophagen Pharmaceutical, Tokyo, Japan) at a dose of
40 mL
 
/
 
day, which was discontinued on 24 December
1996 due to marked improvement of the patient’s liver
function test.
On 24 August 1998, approximately 20 months after
her first attack, the patient was readmitted to the local
hospital with an abnormal liver function test and was
given SNMC along with a daily dose of 300 mg urso-
deoxycholic acid (UDCA). Being referred from that
nearby hospital, she was admitted to our hospital for
the first time on 14 September 1998. On admission, the
patient was alert with normal body temperature. Vital
signs were normal and she had a good appetite. Physical
examination did not reveal anemia, hepatomegaly,
splenomegaly or ascites. The laboratory data on admis-
sion to our hospital are given in Table 1. The patient had
normal levels of serum total bilirubin (0.5 mg/dL), but the
levels of liver enzymes in the sera were moderately
elevated (AST 77 IU/L; ALT 193 IU/L; 
 
γ
 
-GTP 99 IU/L;
ALP 172 IU/L). Serum IgG was 2000 mg/dL and the
titers of autoantibodies were not markedly elevated.
Major histocompatibility complex (MHC) typing indicated
that she had HLA-DR1 and HLA-DR2. She was negative
for markers of hepatitis viruses, except for transfusion-
transmitted virus DNA. No abnormality was found on
abdominal ultrasonography and upper gastrointestinal
endoscopy. The size of the liver, spleen and pancreas was
normal. Thirty-seven days after onset of this episode, a
liver biopsy was obtained under ultrasonography, which
revealed expansion of portal areas with an infiltration of
mononuclear cells containing approximately 5% plasma
cells (Fig. 2a). Focal necrosis (one to three per lobule)
and interface hepatitis were also detected in the liver
specimen. According to a modified histologic activity
index (HAI) score, the histological diagnosis was chronic
hepatitis with moderate activity and mild fibrosis. The
patient scored 11 points according to the scoring system
recommended by the International Autoimmune Hepatitis
Group and she was diagnosed as ‘probable AIH’. She
was given 600 mg/day UDCA and her liver function tests
soon improved. The patient was discharged and was
followed up at our out-patient department.
After approximately 3 years, on 10 October 2001, the
patient developed high fever (39
 
°
 
C), chilliness and nasal
obstruction. Although she became afebrile the following
day, general fatigue, abdominal discomfort and symp-
toms suggestive of a common cold continued. This led
her to take analgesic drugs, such as acetoaminophen,
isopropamide and diclofenac sodium. On 14 October
2001, the patient noticed itching and dark urine and was
admitted to our hospital on 17 October 2001 (Fig. 1).
On admission, the patient complained of poor appe-
tite and jaundice, but no abdominal pains. On examina-
tion, the liver was found to be enlarged and palpable
(two to three fingers in breadth below the right costal
margin). As shown in Table 1, increased levels of total
bilirubin and liver enzymes were detected at this time.
The ANA titer was elevated (1 : 40). The drug-induced
lymphocyte stimulating test was negative for aceto-
aminophen, isopropamide and diclofenac sodium. Two
stones were detected in the gall-bladder by abdominal
ultrasonography. Two days later, upper gastrointestinal
 
Table 1
 
Laboratory data
September 1998 October 2001
Total bilirubin (0.2–0.8 mg/dL) 0.5 mg/dL 2.2 mg/dL
Alanine aminotransferase (3–49 IU/L) 193 IU/L 874 IU/L
Asparate aminotransferase (9–37 IU/L) 77 IU/L 600 IU/L
 
γ
 
-Glutamyl transpeptidase (6–71 IU/L) 99 IU/L 198 IU/L
 
γ
 
-Globulin (8.6–20%) 21.9% 21.9%
IgG (870–1700 mg/dL) 2000 mg/dL 2010 mg/dL
IgM (35–220 mg/dL) 116 mg/dL 114 mg/dL
Antinuclear antibody (< 1 : 20) 1 : 20 1 : 40
Antismooth muscle antibody (< 1 : 20) 1 : 20 1 : 20
Antimitochondrial antibody (1 : 20) 1 : 20 < 1 : 20
Anti-M2 antibody (< 20 U/mL) < 4 U/mL < 4 U/mL
Anti-liver kidney microsomal antibody (< 17 U) < 1 U < 5 U
C-Reactive protein (< 0.25 mg/dL) < 0.25 mg/dL ND
Rheumatoid arthritis factor < 11 IU/mL ND
Lupus erythromatous phenomenon Negative ND
 
Figures in parentheses indicate the normal range.
ND, not done.
108 S KARIM ET AL.
endoscopy showed erosive gastritis with antral atrophy
and gastric ulcer. No abnormality was detected by
magnetic resonance cholangiopancreatography.
A liver biopsy was performed on 23 October 2001
(7th admission day) under laparoscopy. This revealed an
expansion of portal areas with portal–portal and portal–
central bridging fibrosis. A moderate degree of lympho-
cyte infiltration into the portal tracts was observed and
there were five to six focal necroses per lobule (Fig. 1).
However, laparoscopic findings showed no evidence of
reddish or whitish markings and depressions on the
surface of the liver. The score for the diagnosis of AIH
remained as before. Itching and skin rashes subsided.
From 14th day of admission (30 October 2001), 40 mg/
day prednisolone was prescribed, which was tapered
subsequently. Due to an improvement of the patient’s
general condition and liver function tests, prednisolone
was discontinued from 1 June 2002 and she was given
UDCA (600 mg/day). The patient is currently under
supervision at our out-patient department.
DISCUSSION
Autoimmune hepatitis is a chronic liver disease with an
autoimmune etiology, which takes a variable course and
usually responds well to immunosuppressive therapy.1–4
Herein, we report on a case of AIH showing acute
exacerbation and subsequent spontaneous remission.
Although the patient experienced three attacks of
acute hepatitis within the past 5 years, spontaneous
remission of AIH was achieved in the first two episodes,
whereas prednisolone therapy was required for the
management of her last and most recent attack.
The diagnosis of this patient is important. The first
attack of acute hepatitis, which she experienced in 1996
in a nearby hospital, was characterized by marked eleva-
tion of direct bilirubin and liver enzymes. Infection with
hepatitis virus and drug-induced hepatitis were ruled out.
Increased titers of ANA supported a clinical diagnosis
of AIH; however, a histological diagnosis of AIH could
not be made at that time due to a lack of a liver biopsy
specimen.
The second attack of acute hepatitis, which was com-
paratively milder than the first, was characterized by
increased levels of IgG in addition to elevated levels of
liver enzymes. Moreover, a histological diagnosis of AIH
was suggested from the presence of plasma cells in the
portal areas.
The role of UDCA in bringing about a remission of AIH
is controversal. Nakamura et al. have suggested a favor-
able effect of UDCA in AIH after using UDCA for 1 year;8
however, Czaja et al. did not find any therapeutic role for
UDCA in AIH.9 In the present case, remission of AIH con-
tinued even after the cessation of UDCA, indicating that
the contribution of UDCA, if any, would be insignificant
for the remission of AIH.
Although drug-induced hepatitis due to diclofenac
sodium may underlie the third and most recent attack of
Fig. 2 Microscopic pictures of liver biopsy specimens taken on
1 October 1998 during the  patient’s second admission (a) and
on 23 October 2001 during her third admission (b) to Ehime
University Hospital.  Expansion of the portal area (arrows),
destruction of limiting plates (asterisk) and infiltration of mono-
nuclear cells (arrowheads) are seen.  Infiltration of mononuclear
cells is also expanding into the hepatic parenchyma and liver
sinusoids in (b). (Hematoxylin eosin staining.)
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hepatitis, this possibility was completely discarded on the
basis of the clinical history, laboratory investigations and
histological findings. The patient took the drug on
12 October 2001 and was admitted with frank jaundice
to our hospital on 17 October 2001. Hepatic injury due
to diclofenac sodium may develop 1–44 weeks after the
intake of this drug.
 
8
 
 In exceptional cases, the minimum
period between the intake of this drug and a fatal attack
of acute hepatitis has been reported to be 4 days.
 
10
 
 Our
patient took this drug only once and it is evident that she
already had liver injury before taking the drug. Moreover,
peripheral eosinophilia with rash, only eosinophilia
or only rash are characteristic features of diclofenac-
induced hepatitis; none of these features was present in
our patient. The drug lymphocyte stimulation test was
also negative for diclofenac sodium.
A diagnosis of AIH was also supported by rising titers
of ANA (which was 1 : 80 during the first attack and
elevated to 1 : 160 during the first remission), although
this was not very high, and elevated serum levels of IgG.
The pattern of ANA (homogeneous and speckled) also
sugested a diagnosis of AIH.
 
1–4
 
 The patient’s MHC typing
also indicated a possible diagnosis of AIH. Obermayer
 
et al
 
. have reported that there is a significant association
between HLA-DR2 and Japanese patients with AIH.
 
3
 
Patients with AIH are characterized by relapses and
remissions, although this is mostly achieved by immuno-
suppressive drugs and few cases with spontaneous remis-
sion have been reported.
 
7
 
 The point that we would like to
emphasise is the course of illness in our patient. Although
her transaminase levels reached as high as 10-fold the
upper limit of normal, she had a spontaneous remission
without immnuosuppressive drugs. Although the present
case mimics acute AIH
 
5,6
 
 from the viewpoint of acute
exacerbation and spontaneous remission, histological
features showed expansion of the portal tracts, destruc-
tion of the limiting plates and the presence of fibrosis (i.e.
features of AIH). The future clinical course of this patient
may provide an insight into the transition of acute AIH to
chronicity or remission.
It is not known why this patient has had three attacks of
acute exacerbation during the past 5 years. Hepatitis A
virus and drugs are known to trigger AIH
 
11
 
 and Lohse
 
et al
 
.
 
7
 
 have reported the spontaneous remission of AIH.
The present patient was not infected with hepatitis A virus
and a role of drugs in the induction of AIH could not be
documented. The immunoreactivity of the host to its
own autoantigens may be altered with the progression of
disease or a protracted prodormal period may be neces-
sary before a clinical attack is observed.
Immunosuppressive therapy has been withdrawn from
this patient from 1 June 2002. She is now under follow up
at our out-patient department and it will be interesting to
evaluate how long the quality of life of this patient can be
maintained without immunosuppressive therapy.
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